Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00219635 · ClinicalTrials.gov registry record · Phase 2
Assessment Of Efficacy and Safety UK-390,957 In Men With Premature Ejaculation
A Phase 2 study of Ejaculation, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 138
- Enrollment target
- 20
- Study locations
NCT00219635 is a Phase 2 study of Ejaculation that has completed, run by Pfizer. The registered enrollment target is 138 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT00219635, a Phase 2 study of Ejaculation, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 138 participants
- Enrollment target
- 20
- Study locations
Study Summary
Assessment of efficacy and safety UK-390,957
Conditions Studied
Interventions
- DRUG UK-390,957
Study Locations (20)
Ontario
- Pfizer Investigational Site - Barrie
- Pfizer Investigational Site - London
- Pfizer Investigational Site - Toronto
Missouri
- Pfizer Investigational Site - Kansas City
- Pfizer Investigational Site - Washington
New York
- Pfizer Investigational Site - New York
- Pfizer Investigational Site - Williamsville
Texas
- Pfizer Investigational Site - Dallas
- Pfizer Investigational Site - Houston
Alabama
- Pfizer Investigational Site - Birmingham
California
- Pfizer Investigational Site - San Bernardino
Louisiana
- Pfizer Investigational Site - Metairie
Massachusetts
- Pfizer Investigational Site - Watertown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2005-01 |
| Est. Completion | 2005-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00219635
The ClinicalTrials.gov registry entry for NCT00219635 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 138 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ejaculation appearing as the primary indexed condition, and to 1 intervention - of which UK-390,957 is the first listed.
NCT00219635 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Ontario, Missouri, New York.
Frequently Asked Questions
What is clinical trial NCT00219635 about?
NCT00219635 is a clinical study titled "Assessment Of Efficacy and Safety UK-390,957 In Men With Premature Ejaculation". Assessment of efficacy and safety UK-390,957
What is the current status of trial NCT00219635?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 138 participants. The study started on 2005-01. Estimated completion is 2005-07.
What conditions does trial NCT00219635 study?
This clinical trial studies the following conditions: Ejaculation.
What interventions are being tested in trial NCT00219635?
The interventions under investigation include: UK-390,957 (DRUG).
Who is sponsoring clinical trial NCT00219635?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00219635 being conducted?
This trial has 20 study locations across Alabama, California, Louisiana, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ejaculation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.